Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HNF4α srRNA in advanced intrahepatic cholangiocarcinoma
NCT06583993Phase 1Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Nov 2024
- Primary completion
- May 2026
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hnf4α srRNA in intrahepatic cholangiocarcinoma (ICC), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Tolerability and Safety. Started Nov 2024; status: recruiting.
02
Drugs
hnf4α srRNA
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06583993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06583993.